BioLineRx (BLRX) Cash & Equivalents (2021 - 2025)

BioLineRx has reported Cash & Equivalents over the past 5 years, most recently at $3.2 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $3.2 million for Q4 2025, down 68.86% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (down 68.86% YoY), and the annual figure for FY2025 was $3.2 million, down 68.86%.
  • Cash & Equivalents for Q4 2025 was $3.2 million at BioLineRx, down from $10.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for BLRX hit a ceiling of $13.0 million in Q4 2021 and a floor of $3.2 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $10.4 million (2024), compared with a mean of $8.3 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 145.26% in 2024 and later tumbled 68.86% in 2025.
  • BioLineRx's Cash & Equivalents stood at $13.0 million in 2021, then decreased by 18.5% to $10.6 million in 2022, then plummeted by 59.81% to $4.3 million in 2023, then skyrocketed by 145.26% to $10.4 million in 2024, then tumbled by 68.86% to $3.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $3.2 million (Q4 2025), $10.4 million (Q4 2024), and $4.3 million (Q4 2023) per Business Quant data.